131 related articles for article (PubMed ID: 32024338)
1. Thyroid disturbances in children treated with combined pegylated interferon-alpha and ribavirin for chronic hepatitis C.
Rashed YK; Khalaf FA; Kotb SE
Clin Exp Pediatr; 2020 Feb; 63(2):52-55. PubMed ID: 32024338
[TBL] [Abstract][Full Text] [Related]
2. Transient Hypothyroidism and Autoimmune Thyroiditis in Children With Chronic Hepatitis C Treated With Pegylated-interferon-α-2b and Ribavirin.
Serranti D; Indolfi G; Nebbia G; Cananzi M; D'Antiga L; Ricci S; Stagi S; Azzari C; Resti M;
Pediatr Infect Dis J; 2018 Apr; 37(4):287-291. PubMed ID: 28953189
[TBL] [Abstract][Full Text] [Related]
3. Incidence of and risk factors for thyroid dysfunction during peginterferon α and ribavirin treatment in patients with chronic hepatitis C.
Hwang Y; Kim W; Kwon SY; Yu HM; Kim JH; Choe WH
Korean J Intern Med; 2015 Nov; 30(6):792-800. PubMed ID: 26552454
[TBL] [Abstract][Full Text] [Related]
4. Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: incidence, associated factors and prognosis.
Kee KM; Lee CM; Wang JH; Tung HD; Changchien CS; Lu SN; Wang PW
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):319-26. PubMed ID: 16460494
[TBL] [Abstract][Full Text] [Related]
5. [Clinical observation of Hashimoto thyroiditis in patients with chronic hepatitis C undergoing pegylated-interferon alpha-2a and ribavirin combination therapy].
Teng ZL; Gong WJ; Zhang SQ; Sun YX; Ma XH
Zhonghua Gan Zang Bing Za Zhi; 2013 Feb; 21(2):101-4. PubMed ID: 23663880
[TBL] [Abstract][Full Text] [Related]
6. Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.
Friedrich-Rust M; Theobald J; Zeuzem S; Bojunga J
J Viral Hepat; 2009 Mar; 16(3):168-77. PubMed ID: 19175874
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes and risk factors of thyroid dysfunction during pegylated interferon and ribavirin treatment in patients with chronic hepatitis C infection in Taiwan.
Chang YK; Tseng YT; Chen KH; Chen KT
BMC Endocr Disord; 2019 Apr; 19(1):36. PubMed ID: 30953492
[TBL] [Abstract][Full Text] [Related]
8. The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism.
Carella C; Mazziotti G; Morisco F; Rotondi M; Cioffi M; Tuccillo C; Sorvillo F; Caporaso N; Amato G
Eur J Endocrinol; 2002 Jun; 146(6):743-9. PubMed ID: 12039693
[TBL] [Abstract][Full Text] [Related]
9. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
[TBL] [Abstract][Full Text] [Related]
10. Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy.
Dalgard O; Bjøro K; Hellum K; Myrvang B; Bjøro T; Haug E; Bell H
J Intern Med; 2002 May; 251(5):400-6. PubMed ID: 11982739
[TBL] [Abstract][Full Text] [Related]
11. Thyroid dysfunction in patients with chronic hepatitis C: virus- or therapy-related?
Vezali E; Elefsiniotis I; Mihas C; Konstantinou E; Saroglou G
J Gastroenterol Hepatol; 2009 Jun; 24(6):1024-9. PubMed ID: 19383078
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of thyroid dysfunction and influencing factors in chronic hepatitis C patients treated with peg-IFNa-2a and ribavirin].
Huang YX; Chen XY; Ma LN; Yin JM; Ren S; Guo DD; Zheng YH
Zhonghua Gan Zang Bing Za Zhi; 2012 Mar; 20(3):216-20. PubMed ID: 22475143
[TBL] [Abstract][Full Text] [Related]
13. Thyroid Dysfunction in Chronic Hepatitis C Patients Treated with the Combined Pegylated Interferon-Ribavirin Therapy.
Hamza I; Eid Y; El-Sayed M; Marzaban R; Abdul-Kareem S
J Interferon Cytokine Res; 2016 Sep; 36(9):527-33. PubMed ID: 27333271
[TBL] [Abstract][Full Text] [Related]
14. Central hypothyroidism and hypophysitis during treatment of chronic hepatitis C with pegylated interferon alpha and ribavirin.
Ridruejo E; Christensen AF; Mando OG
Eur J Gastroenterol Hepatol; 2006 Jun; 18(6):693-4. PubMed ID: 16702862
[TBL] [Abstract][Full Text] [Related]
15. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
[TBL] [Abstract][Full Text] [Related]
16. [Thyroid dysfunctions in children with chronic hepatitis C during interferon alpha-2b therapy].
Kupś-Rzepecka J; Woźniakowska-Gesicka T; Gołabek V
Przegl Lek; 2011; 68(6):311-5. PubMed ID: 22039668
[TBL] [Abstract][Full Text] [Related]
17. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.
Lee SD; Yu ML; Cheng PN; Lai MY; Chao YC; Hwang SJ; Chang WY; Chang TT; Hsieh TY; Liu CJ; Chen DS
J Viral Hepat; 2005 May; 12(3):283-91. PubMed ID: 15850469
[TBL] [Abstract][Full Text] [Related]
18. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
[TBL] [Abstract][Full Text] [Related]
19. Interferon-alpha induced and ribavirin induced thyroid dysfunction in patients with chronic hepatitis C.
Nadeem A; Hussain MM; Aslam M; Hussain T
Hepat Mon; 2010; 10(2):132-40. PubMed ID: 22312386
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes of thyroid dysfunction in patients with chronić hepatitis C treated with pegylated interferon alpha and ribavirin.
Kozielewicz D; Wietlicka-Piszcz M; Halota W
Przegl Epidemiol; 2017; 71(4):555-569. PubMed ID: 29415534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
